2nd International Symposium on the Economics of Asthma and Asthma Care

A Free Pre-Congress Symposium to the 9th World Congress on Health Economics Sydney, Australia, Saturday July 6, 2013
Sydney Convention and Exhibition Centre, Darling Harbour, Bayside 204B

Key Presenters
Larry Lynd, PhD, BSP, University of British Columbia and AllerGen Networks of Centres of Excellence (NCE), Canada Larry Lynd is Associate Professor and Associate Director of the Collaboration for Outcomes Research and Evaluation in the Faculty of Pharmaceutical Sciences, an Associate in the School of Population and Public Health, and a Scientist at the Centre for Health Evaluation and Outcomes Sciences at the University of British Columbia. He is the Co-PI of the AllerGen Networks of Centres of Excellence Platform for Outcomes Research and Translation in Asthma and Allergy (PORTAL), and he is the principal investigator of a CIHR New Emerging Team Grant for Rare Diseases. He is also a member of the Health Canada Special Advisory Committee for Respiratory and Allergy Therapies. His primary research interests involve benefit-risk analysis, pharmaco-epidemiology and health outcomes research, and health policy related to orphan drugs. Dr. Richard Loh, University of Western Australia, Perth, Australia Associate Professor Richard Loh is the Head of the Immunology Department at Princess Margaret Hospital and Clinical Associate Professor at the University of Western Australia. Richard is a graduate of the University of Queensland and trained in Immunology and Allergy at the Children's Hospital in Boston and Harvard Medical School. He is the President of ASCIA and a member of the AAAAI Anaphylaxis Committee. He is actively involved in anaphylaxis management and chaired the ASCIA Anaphylaxis Working Party for 4 years during which time they developed online anaphylaxis training. Richard is the Chair of the Anaphylaxis Expert Committee which is developing an anaphylaxis model of care in Western Australia, as well as a member of the WA Anaphylaxis Project Advisory Group.

www.allergen-nce.ca

Dr. Mohsen Sadatsafavi , MD, PhD, Department of Medicine, University of British Columbia (UBC) & AllerGen NCE, Canada Mohsen Sadatsafavi is an Assistant Professor of Health Economics and Outcomes Research at the Division of Respiratory Medicine, Department of Medicine, University of British Columbia. He is also a scientist at the Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute, and is an affiliate in the Collaboration for Outcomes Research and Evaluation at UBC. Dr. Sadatsafavi's program of research encompasses three components of clinical studies, analysis of administrative health databases, and decision-analytic modeling of chronic respiratory conditions. Since starting his academic appointment at UBC in July 2012, he has been involved in several studies, including: the comparative effectiveness of competing treatments for asthma; measuring the preventable productivity loss in asthma; impact of the specialty of care on long-term outcomes in asthma and COPD; the humanistic and economic benefit of following asthma treatment guidelines, and; benefit risk analysis of various screening strategies for latent tuberculosis infection. Dr. Wendy Ungar, PhD, MSc, Hospital for Sick Children, University of Toronto and AllerGen NCE, Canada Wendy Ungar is a Senior Scientist in Child Health Evaluative Sciences at The Hospital for Sick Children, Toronto, Canada, an Associate Professor in Health Policy, Management and Evaluation, University of Toronto, and an Adjunct Scientist at the Institute for Clinical Evaluative Sciences. Dr. Ungar leads a program of research in the application of health economic methods to the paediatric population and also investigates the relationship between policies governing access to prescription medicines and health outcomes in children with asthma. Dr. Ungar directs TASK (Technology Assessment at The Hospital for Sick Children), a health technology assessment research unit focusing on technology assessment of pediatric health interventions. In 2010, Dr. Ungars book, Economic Evaluation in Child Health, was published by Oxford University Press.

www.allergen-nce.ca

SATURDAY, JULY 6, 2013

8:30 AM 9:15 9:30 AM

REGISTRATION AND LIGHT BREAKFAST WELCOME AND OPENING REMARKS

Diana Royce, EdD, Managing Director and COO, AllerGen NCE Inc., Canada

Bayside 204B Bayside 204B

9:30 10:30 AM

OPENING KEYNOTE PRESENTATION: WHERE DO WE STAND IN THE ECONOMICS OF ASTHMA AND ASTHMA CARE?
Larry Lynd, PhD, University of British Columbia and AllerGen NCE, Canada The introduction of inhalers 50 years ago, and in particular salbutamol and beclomethasone, radically changed the treatment of asthma. For decades, however, there was little advancement in treatment options. Today, the advent of biologics, personalized medicine and bronchial thermoplasty offer new possibilities for the effective, targeted diagnosis and treatment options of asthma. This session will provide an overview of the economic implications of the current state of asthma and asthma care as it relates to the current drug pipeline, new treatments and the continuing challenge of treatment adherence.

Bayside 204B

10:30 11:00 AM BREAK 11:00 12:15 PM

WHAT DO WE REALLY KNOW ABOUT THE ECONOMIC COST OF ASTHMA?

Mohsen Sadatsafavi, MD, PhD, University of British Columbia & AllerGen NCE, Canada Analysis of Asthma and Asthma Care Costs from a Canadian Perspective

Bayside 204B

Ning Yan Gu, PhD, University of New Mexico, USA Predicting Healthcare Costs in Asthma using the EQ-5D Health-Related Quality-ofLife Index Score

12:15 1:00 PM 1:00 1:45 PM

NETWORKING LUNCH LUNCH KEYNOTE PRESENTATION: NATIONAL ANAPHYLAXIS STRATEGY IN AUSTRALIA - LESSONS FOR ASTHMA
Dr. Richard Loh, University of Western Australia, Perth, Australia Dr. Loh was instrumental in developing a successful Anaphylaxis Strategy in Western Australia that has helped meet the challenges of severe life-threatening allergy head-on. Dr. Loh will offer thoughts on how to apply this successful program to asthma.
Bayside 204B

www.allergen-nce.ca

1:45 2:30 PM

INTERACTIVE SESSION: BUILDING A NATIONAL ASTHMA STRATEGY

This session is designed to allow both presenters and the audience a chance to discuss how to take lessons from the Australian Anaphylaxis Strategy and apply them to the development of a workable national asthma strategy: What are the 3-5 most important lessons from the Australian Anaphylaxis Strategy? What specific features/foci are essential to the development of a national asthma strategy? What country-specific, culture-specific barriers need to be overcome? How should stakeholder groups including patients, academics, industry and policy makers be involved in the implementation of a national asthma strategy and what role should they play?

Bayside 204B

Chair: Diana Royce, EdD, Managing Director and COO, AllerGen NCE, Canada

2:30 3:00 PM 3:00 4:15 PM

BREAK UNDERSTANDING ASTHMA CONTROL

Lilla Roy, MSc Student, University of British Columbia, Canada and AllerGen NCE, Canada Evaluating preferences for long term wheeze following RSV infection using TTO and Best-Worst Scaling Wendy Ungar, PhD, MSc, Hospital for Sick Children, University of Toronto and AllerGen NCE, Canada Achieving Asthma Control in Children: What Do Parents and Adolescents think is Important?
Bayside 204B

4:15 4:30 PM

NEXT STEPS AND CLOSING REMARKS

Diana Royce, EdD, Managing Director and COO, AllerGen NCE , Canada Bill Swan, Deputy CEO, International Health Economics Association, Nova Scotia, Canada

Bayside 204B

www.allergen-nce.ca

Organizing Committee:
Chair: Dr. Diana Royce, EdD, AllerGen NCE, Canada Members: Dr. Mohsen Sadatsafavi, MD, PhD, University of British Columbia & AllerGen NCE, Canada Bill Swan, Deputy CEO, International Health Economics Association; Chair, National Asthma Patient Alliance; Board Member, Asthma Society of Canada, Member, Health Canada Special Advisory Committee for Respiratory and Allergy Therapies, Nova Scotia, Canada Dr. Wendy Ungar, PhD, MSc, Hospital for Sick Children, University of Toronto & AllerGen NCE, Canada Dr. Carlo Marra, PharmD, PhD, Associate Professor & Director, CORE | Faculty of Pharmaceutical Sciences, University of British Columbia & AllerGen NCE, Canada

AllerGen NCE Inc., the Allergy, Genes and Environment Network, (est. 2004), is a national research network funded by Industry Canada through the Networks of Centres of Excellence (NCE) Program. AllerGens mandate is to support research, networking, commercialization, knowledge mobilization and capacity building activities that contribute to reducing the morbidity, mortality and socio-economic impacts of asthma, allergy and anaphylaxis. www.allergen-nce.ca

www.allergen-nce.ca